PATENT CLAIM ANALYSIS

Application Number: 15937564
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "312000"]

Abstract:
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), their pharmaceutical compositions, and methods of treating cystic fibrosis in patients with residual function mutations.

Claim (Index 1):
A method of treating cystic fibrosis in a patient, comprising administering to the patient an effective amount of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound I): or a pharmaceutically acceptable salt thereof and N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Compound II): or N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Compound II-d): or a pharmaceutically acceptable salt of either,\n wherein the patient has at least one E831X cystic fibrosis transmembrane conductance regulator (CFTR) mutation.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 90.0
- Lexical Diversity: 1.07692
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15125827', '13439379', '15747290', '14877914', '12909789']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7835287754561896
- 35 USC 102 Novelty (BERT): 0.5177517535817189
- Combined Prediction Score: 0.7569510732687426
- Mean Citation Score: 311.545706
- Max Citation Score: 321.45975
- Similarity Product: 236.60200233654683

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test